Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NASDAQ:CRBU NASDAQ:HYPD NASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$9.17-1.6%$8.75$7.12▼$20.56$172.68M2.55426,818 shs172,702 shsCRBUCaribou Biosciences$1.57-3.7%$1.85$1.38▼$3.54$155.71M2.362.49 million shs946,733 shsHYPDHyperion DeFi$2.51-4.9%$3.18$2.49▼$15.00$40.02M2.49280,843 shs268,030 shsIPHAInnate Pharma$1.78+1.1%$1.82$1.17▼$2.63$165.30M0.327,593 shs2,542 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-1.61%+1.78%+12.10%-8.85%+4.32%CRBUCaribou Biosciences-3.68%-4.85%-5.42%-26.29%-36.69%HYPDHyperion DeFi-4.92%-8.39%-26.18%-39.81%-73.07%IPHAInnate Pharma+1.14%+1.71%-6.32%+26.24%-10.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$9.17-1.6%$8.75$7.12▼$20.56$172.68M2.55426,818 shs172,702 shsCRBUCaribou Biosciences$1.57-3.7%$1.85$1.38▼$3.54$155.71M2.362.49 million shs946,733 shsHYPDHyperion DeFi$2.51-4.9%$3.18$2.49▼$15.00$40.02M2.49280,843 shs268,030 shsIPHAInnate Pharma$1.78+1.1%$1.82$1.17▼$2.63$165.30M0.327,593 shs2,542 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-1.61%+1.78%+12.10%-8.85%+4.32%CRBUCaribou Biosciences-3.68%-4.85%-5.42%-26.29%-36.69%HYPDHyperion DeFi-4.92%-8.39%-26.18%-39.81%-73.07%IPHAInnate Pharma+1.14%+1.71%-6.32%+26.24%-10.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 2.64Moderate Buy$40.67343.48% UpsideCRBUCaribou Biosciences 2.75Moderate Buy$8.67452.02% UpsideHYPDHyperion DeFi 2.25Hold$6.95176.89% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00180.90% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, CRBU, CRBP, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CRBPCorbus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/26/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $34.006/17/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$54.00 ➝ $52.006/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.306/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/ACRBUCaribou Biosciences$11.20M13.90N/AN/A$1.31 per share1.20HYPDHyperion DeFi$1.04M36.48N/AN/A$4.73 per share0.53IPHAInnate Pharma$2.79M59.99N/AN/A($0.26) per share-6.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)CRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/12/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A2.18N/AN/A-91.59%-73.08%N/AIPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)Latest HYPD, CRBU, CRBP, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026CRBUCaribou Biosciences-$0.33N/AN/AN/A$2.28 millionN/A8/11/2026Q2 2026CRBPCorbus Pharmaceuticals-$1.30N/AN/AN/AN/AN/A5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A7.927.92CRBUCaribou BiosciencesN/A6.226.22HYPDHyperion DeFi0.121.971.97IPHAInnate PharmaN/A1.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%CRBUCaribou Biosciences77.51%HYPDHyperion DeFi25.84%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.50%CRBUCaribou Biosciences8.54%HYPDHyperion DeFi7.50%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataIPHAInnate Pharma22093.92 million63.97 millionNot OptionableHYPD, CRBU, CRBP, and IPHA HeadlinesRecent News About These CompaniesOncolytics Biotech (NASDAQ:ONCY) versus Innate Pharma (NASDAQ:IPHA) Critical ContrastJuly 24 at 2:14 AM | americanbankingnews.comInnate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology ConferenceJuly 23 at 1:00 AM | businesswire.comInnate Pharma Corporate Event Calendar | NASDAQ:IPHAJuly 5, 2026 | benzinga.comInnate Pharma to participate in the Jefferies Global Healthcare ConferenceMay 19, 2026 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comInnate Pharma Reports First Quarter 2026 Business Update and Financial ResultsMay 13, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 16, 2026May 12, 2026 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Q1 2026 Business UpdateMay 6, 2026 | businesswire.comInnate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | finanznachrichten.deInnate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | businesswire.comInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026April 17, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026April 13, 2026 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026April 13, 2026 | businesswire.comInnate Pharma SA Sponsored ADRApril 8, 2026 | edition.cnn.comInnate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventApril 8, 2026 | businesswire.comInnate Pharma to Participate in the Kempen Life Sciences ConferenceApril 3, 2026 | businesswire.comInnate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual ReportApril 2, 2026 | businesswire.comInnate Pharma S.A. (IPHA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comInnate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocusMarch 26, 2026 | fiercebiotech.comFInnate Pharma SA: Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateMarch 26, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, CRBU, CRBP, and IPHA Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$9.17 -0.15 (-1.61%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.18 +0.01 (+0.11%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Caribou Biosciences NASDAQ:CRBU$1.57 -0.06 (-3.68%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Hyperion DeFi NASDAQ:HYPD$2.51 -0.13 (-4.92%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.51 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Innate Pharma NASDAQ:IPHA$1.78 +0.02 (+1.14%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/24/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
